Table 2.
Select Lipid-Based Products in Clinical Development
| Therapeutic | Product Name | Sponsor | Indication | Trial Phase |
|---|---|---|---|---|
| BLP-25a | Stimuvax | Merck | Nonsmall cell lung cancer | Phase III |
| Cytarabine | CPX-351 | Celator | Acute myeloid leukemia | Phase III |
| MHC Ib | Allovectin-7 | Vical Inc. | Metastatic melanoma | Phase III |
| Cisplatin | Lipoplatin | Regulon | Nonsmall cell lung cancer | Phase III |
| SPI-77 | NYU | Ovarian cancer | Phase II | |
| Aroplatin | NYU | Malignant mesothelioma | Phase II | |
| Doxorubicin | ThermoDox | Celsion | Primary hepatocellular carcinoma | Phase III |
| Refractory chest wall breast cancer | Phase II | |||
| Colorectal liver metastases | Phase II | |||
| 2B3-101 | To-BBB | Brain metastases and glioma | Phase II | |
| Meningeal carcinomatosis | Phase II | |||
| MPL/QS21c | RTS,S/ASO1B | GSK | Malaria | Phase II |
| Oxaliplatin | MBP-426 | Mebiopharm | Gastrointestinal adenocarcinoma | Phase II |
| Paclitaxel | LEP—ETU | Insys | Breast cancer | Phase II |
| EndoTAG-1 | MediGene | Breast cancer | Phase II | |
| PNU-91934 | MSKCC | Esophageal cancer | Phase II | |
| SN38d | CPX-1 | Celator | Colorectal cancer | Phase II |
| LE-SN38 | C&L Grp B | Metastatic colorectal cancer | Phase II | |
| MM-398 | Merrimack | Gastric and pancreatic cancer | Phase II |
The BLP-25 lipopeptide is a 25-amino-acid protein sequence (STAPPAHGVTSAPDTRPAPGSTAPP) containing a palmitoyl lysine residue at the carboxy terminal. BLP-25 provides specificity of the mucin 1 (MUC1) integral membrane protein to stimulate an anti-MUCl immune response.
Allovectin-7 is a cancer immunotherapeutic formulated as a plasmid/cationic lipid complex containing DNA sequences encoding HLA-B7 and beta-2-microglobulin—the heavy and light chains of the major histocompatibility complex (MHC) class I, respectively.
RTS,S/AS01B is a recombinant hybrid peptide malaria candidate vaccine formulated as a liposome adjuvant system with immunostimulants monophosphoryl lipid A (MPL) and QS21 (a natural saponin that is the purification fraction 21 from the bark of the South American tree Quillaja saponaria).
SN38 (7-ethyl-10-hydroxy-camptothecin) is the active metabolite of prodrug irinotecan (CPT-11), converted through carboxylesterase enzymes.
C&L Grp B, Cancer and Leukemia Group B; GSK, GlaxoSmithKline; MSKCC, Memorial Sloan-Kettering Cancer Center; and NYU, New York University School of Medicine.